NCI Begins Enrollment in Precision Medicine Trial for Childhood Cancers

0NCI Begins Enrollment in Precision Medicine Trial for Childhood Cancers. The study is the pediatric counterpart to an ongoing precision medicine study in cancer patients 18 years and older. Read more >
0FDA, NCI Memorandum Indicates Growing Interest in Proteogenomics as Clinical ApproachWhile proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official. Read more >
0LabCorp Q2 Revenues Rise 5 Percent, Fueled by Diagnostics GrowthTotal revenues reached $2.54 billion during the quarter, while LabCorp Diagnostics’ revenues rose more than 8 percent to $1.80 billion. Read more >
0Late-Onset Preeclampsia Markers Proposed From Proteomic StudyInvestigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia. Read more >
0

0
0

Leave a Reply